FDA Requires Eye Risk Warnings for Ozempic, Zepbound and Other GLP-1s
On Monday, Nov. 9, 2026, the U.S. Food and Drug Administration required manufacturers of 12 different GLP-1 receptor agonist drugs to update their prescribing information with a warning about a rare eye condition called non-arteritic anterior ischemic optic neuropathy (NAION), which can cause permanent vision loss or blindness.
The regulatory action impacts widely used metabolic medications including Novo Nordisk’s Ozempic and Wegovy, alongside Eli Lilly’s Mounjaro, Zepbound, and its oral medication Foundayo, according to Fierce Pharma. The communication published by the agency notes that NAION cases have been reported across all currently marketed products in this drug class.
“We are carefully evaluating the update and will respond to FDA promptly,” a spokesperson for Novo Nordisk told Fierce Pharma.
FDA Reviews Clinical Data Linking GLP-1 Drugs to NAION
The FDA initiated its formal review following a study published in JAMA Ophthalmology involving patients with diabetes, which indicated a potential link between GLP-1 drugs and NAION, as reported by Fierce Pharma.
Additional data from a meta-analysis of 126 randomized clinical trials encompassing 134,253 patients showed an average incidence rate of 6.4 cases per 100,000 person-years for patients on GLP-1 medications, compared with 3.8 cases per 100,000 for those receiving a placebo or alternative treatments, according to findings discussed by MedPage Today and The Conversation.
Retrospective cohort studies conducted by the agency revealed no statistically significant increase in NAION risk when comparing GLP-1 agonists to SGLT-2 inhibitors, though a heightened risk appeared when compared against DPP-4 inhibitors, as noted by MedPage Today. Established risk factors for the condition include smoking, diabetes, hypertension, obstructive sleep apnea, anemia, and chronic kidney disease.
Doctors Advise Patients to Discuss Medication Changes with Physicians
“People with diabetes, high blood pressure, sleep apnea, or a history of smoking may already be at higher risk,” said Dr. Mihail Zilbermint, a professor of clinical medicine at Johns Hopkins Medicine, in an interview with The Baltimore Banner.

“For most of my patients, no,” Zilbermint told The Baltimore Banner when asked if doctors are recommending patients avoid the medications, noting that the cardiovascular, renal, and weight management benefits remain substantial. “My advice is simple: Don’t stop an effective medication because of a headline. Talk to your doctor, and never ignore sudden changes in your vision.”
Healthcare providers are instructed to advise patients to immediately report any sudden onset of acute, painless vision loss or visual field deficits, with affected individuals referred promptly to an ophthalmologist for evaluation.